Veracyte, Inc. (VCYT): Capital Expenditures
$9.68M
Year ended 2025-12-31
$12.39M
Trailing 12 months to 2026-06-30
+4.2%
3-year compound annual growth
+27.8%
5-year compound annual growth
+4.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.68M | -14.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $11.29M | +13.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $9.96M | +16.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $8.55M | +59.0% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $5.38M | +89.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $2.84M | +2.9% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $2.76M | +47.1% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.87M | +6.8% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $1.75M | -58.3% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $4.21M | -31.7% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $6.17M | +204.6% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $2.02M | +52.0% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $1.33M | -8.9% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $1.46M | +429.7% | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | $276.0K | n/a | 2014-03-20, From 2011-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $16.26M | +92.6% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $8.88M | +64.4% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $48.31M | +37.7% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $909.0K | -82.5% |
| Natera, Inc. (NTRA) | 2025-12-31 | $106.19M | +59.9% |
| Fortrea Holdings Inc. (FTRE) | 2025-12-31 | $25.20M | -1.2% |
Compare VCYT, CSTL, CAI, FLGT side by side · Screen every company in Services-Medical Laboratories ↗